| Literature DB >> 34526811 |
Ming Zhong1, Tingting Pan1, Na-Na Sun1, Ruo-Ming Tan1, Wen Xu1, Yu-Zhen Qiu1, Jia-Lin Liu1, Er-Zhen Chen2, Hong-Ping Qu1.
Abstract
OBJECTIVE: To find the predictors for persistent inflammation-immunosuppression catabolism syndrome in ICU surgical septic patients.Entities:
Keywords: persistent inflammation-immunosuppression catabolism syndrome; sepsis
Year: 2021 PMID: 34526811 PMCID: PMC8437379 DOI: 10.2147/IJGM.S331411
Source DB: PubMed Journal: Int J Gen Med ISSN: 1178-7074
Characteristics of Patients
| N=169 | |
|---|---|
| Age (Median IQR) | 65 (54–76) |
| Male, n (%) | 122 (72.19%) |
| BMI (Median IQR) | 22.85 (19.46–25.08) |
| Gastrointestinal | |
| Tumor | 78 (46.15%) |
| ERCP | 8 (4.73%) |
| Emergence | 60 (35.5%) |
| Orthopedics | 5 (2.96%) |
| Urinary | 5 (2.96%) |
| Neurology | 4 (2.36%) |
| Lung | 4 (2.36%) |
| Intra-abdominal | 96 (56%) |
| Lung | 16 (11.83%) |
| Blood | 9 (5.32%) |
| Urinary | 2 (1.18%) |
| Surgical site | 2 (1.18%) |
| Intra-abdominal + Blood | 18 (10.64%) |
| Lung + Blood | 2 (1.18%) |
| Intra-abdominal + Lung | 4 (2.36%) |
| Lung + Blood + Intra-abdominal | 3 (1.78%) |
| Other | 13 (7.69%) |
| Renal | 70 (41.42%) |
| Respiratory | 103 (60.95%) |
| Circulation | 55 (32.54%) |
| Coagulation | 54 (31.95%) |
| Neurologic | 17 (10.06%) |
| Chronic Heart Failure | 14 (8.28%) |
| Tumor | 67 (39.64%) |
| Respiratory | 9 (5.32%) |
| Hypertension | 75 (44.37%) |
| Cirrhosis | 7 (4.14%) |
| Chronic Kidney Disease | 9 (5.32%) |
| Others | 8 (4.73%) |
| APACHE II, median (IQR) | 20 (15–27) |
| CCI, median (IQR) | 2 (1–3) |
| SOFA, median (IQR) | 10 (6–13) |
Propensity Score Matching and Outcomes for Patients
| Before Propensity Score Matching | After Propensity Score Matching | |||||
|---|---|---|---|---|---|---|
| PICS | Non-PICS | P-value | PICS | Non-PICS | P-value | |
| N=47 | N=122 | n=34 | n=55 | |||
| CCI | 4 (2–5) | 2 (1–3) | <0.001a | 3.17±1.4 | 2.8±1.6 | 0.937b |
| SOFA | 11 (9–15) | 9 (6–12) | 0.003a | 10.97±4.33 | 10.87±4.53 | 0.683b |
| BMI | 22.2 (19.5–26.2) | 23.0 (20.2–25.0) | 0.994a | 23.08±4.78 | 22.91±4.01 | 0.147b |
| Age | 67 (56–78) | 65 (51–76) | 0.413a | 65±16 | 65±15 | 0.641b |
| APACHE II | 22 (17–28) | 19.5 (15–25) | 0.025a | 22.02±7.04 | 21.91±8.64 | 0.308b |
| Male | 31 (66%) | 91 (74.6%) | 0.338a | 21 (67.44%) | 39 (70.90) | 0.373b |
| ICU length of stay (days) (IQR) | 29 (20–55)a | 12 (8–26) | <0.005a | 29 (20–55) | 11 (7–27) | <0.001a |
| Hospital length of stay (days) (IQR) | 55 (29–77)a | 43 (23–69) | 0.089a | 43 (25–76) | 54 (26–81) | 0.387a |
| Mortality, n (%) | ||||||
| ICU mortality | 17 (36.2%) | 10 (8.2%) | <0.001c | 11 (32.40%) | 8 (12.4) | 0.046c |
| Mortality 28 days | 5 (10.6%) | 2 (1.6%) | 0.024c | 4 (11.76%) | 2 (3.63%) | 0.067c |
| Mortality 90 days | 18 (38.3%) | 8 (6.6%) | <0.005c | 11 (32.40%) | 5 (9.1%) | 0.006c |
| ICU-acquired infection | 18 (38.29%) | 14 (11.47%) | <0.001c | 15 (44.1%) | 7 (12.7%) | 0.001c |
| Bacteria | 15 (31.91%) | 14 (11.47%) | 0.003c | 12 (35.3%) | 7 (12.7%) | 0.012c |
| Fungi | 3 (6.38%) | 0 (0.00%) | 0.005c | 3 (8.8%) | 0 (0.00) | 0.102c |
Notes: aMann–Whitney test (U-test). bStudent Test (t test). cChi-square test.
Figure 1The Kaplan-Meier survival curve for mortality within 90 days. Log-rank p < 0.01: PICS group had a lower survival rate than non-PICS group.
Laboratory Parameters of Patients
| PICS (n=47) | Non-PICS (n=122) | P-value | |
|---|---|---|---|
| CRP (mg/l) | 95.6 (68.3–170.8) | 120 (49.0–208.3) | 0.426 |
| PCT (ng/dl) | 5.6 (1.5–23.7) | 2.3 (0.78–17.37) | 0.118 |
| Neutrophil count (×109/L) | 10.1 (6.7–15.1) | 11.0 (6.3–15.8) | 0.920 |
| Lymphocyte count (×109/L) | 0.6 (0.4–0.8) | 0.7 (0.4–1.1) | 0.040* |
| NLR | 17.6 (12.5–26.6) | 15.7 (7.4–24.0) | 0.159 |
| Albumin (g/L) | 25.0 (22.0–30.0) | 28 (24.0–34.0) | 0.035* |
| Pre-albumin (g/L) | 76 (56–114) | 85.0 (50.5–118.0) | 0.783 |
| n=47 | n=122 | ||
| CRP (mg/L) | 138 (99.1–222.8) | 131 (73.2–195.6) | 0.370 |
| PCT (ng/dl) | 4.8 (1.4–16.7) | 2.4 (0.6–17.6) | 0.101 |
| Neutrophil count (×109/L) | 10.3 (7.7–15.0) | 9.2 (5.5–13.6) | 0.273 |
| Lymphocyte count (×109/L) | 0.6 (0.4–0.8) | 0.8 (0.5–1.2) | 0.002** |
| NLR | 16.9 (10.3–26.4) | 10.5 (7.2–17.9) | 0.001** |
| Albumin (g/L) | 30.0 (26.5–32.0) | 29.0 (27.0–32.0) | 0.839 |
| Pre-albumin (g/L) | 67.0 (48.0–101.0) | 81.0 (57.0–113.8) | 0.107 |
Notes: All with Mann–Whitney (U-test). *p<0.05. **p<0.01.
The Result of Logistic Regression and ROC Curve
| P-value | OR (95% CI) | |||
|---|---|---|---|---|
| APACHE II | 0.027 | 1.050 (1.005, 1.09) | ||
| Lymphocyte day 1 | 0.025 | 0.407 (0.186, 0.894) | ||
| Lymphocyte day 3 | 0.01 | 0.295 (0.116, 0.752) | ||
| Albumin day 1 | 0.118 | 1.040 (0.990, 1.092) | ||
| NLR day 3 | 0.38 | 1.005 (0.993, 1.017) | ||
| SOFA Score | 0.004 | 1.126 (1.038, 1.221) | ||
| CCI | <0.001 | 1.833 (1.466, 2.290) | ||
| Albumin day 1 | 0.013 | 1.081 (1.016–1.149) | ||
| Lymphocyte day 3 | 0.016 | 0.222 (0.64 0.757) | ||
| SOFA Score | 0.032 | 1.118 (1.015–1.230) | ||
| CCI | <0.001 | 1.911 (1.494–2.443) | ||
| CCI | 0.770 | 0.688–0.853 | <0.001 | 0.616 |
| SOFA | 0.649 | 0.560–0.738 | 0.003 | 0.115 |
| Albumin day 1 | 0.605 | 0.508–0.701 | 0.035 | 0.076 |
| Lymphocyte day 3 | 0.348 | 0.260–0.436 | 0.002 | −1.701 |
| Combined predictor | 0.838 | 0.774–0.901 | <0.001 | |